Tysabri Progressive Multifocal Leukoencephalopathy Attorney: Statute of Limitations for Tysabri in New Jersey

Latest update (2026-07)

Tysabri (natalizumab) PML injury claims continue to be evaluated based on individual monitoring and diagnosis records. [source]

From General Health Science to Occupational Exposure Concerns

The legacy theme of general health and science information provides a broad foundation for understanding how biological systems interact with environmental factors. Within mass production contexts, this foundation extends to examining how industrial processes may introduce specific exposures that affect worker populations. Transitioning from this general health perspective, the focus narrows to occupational settings where employees encounter materials or conditions with potential long-term health implications. In mass production environments, particularly those involving pharmaceutical manufacturing or related chemical handling, workers may face exposure to substances that carry specific risks. One such concern involves the drug Tysabri, used in certain therapeutic contexts, and its association with Progressive Multifocal Leukoencephalopathy (PML). For individuals who have worked in facilities where Tysabri is produced or handled, understanding the legal dimensions of potential exposure becomes critical. This includes awareness of the statute of limitations for filing claims in New Jersey, which governs the timeframe within which affected workers may seek legal recourse. The transition from general health education to this occupational exposure concern requires careful attention to the regulatory and legal frameworks that protect worker rights, without delving into mechanistic disease claims.

Understanding Tysabri and Its Link to PML

Tysabri (natalizumab) is a biologic therapy approved as monotherapy for relapsing forms of multiple sclerosis and for Crohn's disease. Its use carries a well-documented risk of progressive multifocal leukoencephalopathy (PML), a severe opportunistic brain infection caused by the JC virus. The following narrative integrates medical evidence on PML, Tysabri's pharmacology, and legal considerations for affected patients, with a focus on New Jersey's statute of limitations. PML is an opportunistic viral infection of the brain caused by the JC virus (JCV) that typically occurs only in immunocompromised individuals and usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Clinical presentation often includes progressive neurological deficits such as weakness, visual disturbances, cognitive decline, and coordination problems. Diagnosis is confirmed by brain MRI showing characteristic white matter lesions and detection of JCV DNA in cerebrospinal fluid via PCR. Early recognition is critical because Tysabri dosing should be withheld immediately at the first sign or symptom suggestive of PML (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). However, symptoms can be subtle and may mimic multiple sclerosis relapses, leading to diagnostic delays.

Tysabri Pharmacology and Reported Adverse Effects

Tysabri is a monoclonal antibody that binds to alpha-4 integrins on leukocytes, preventing their migration across the blood-brain barrier. This mechanism reduces inflammatory activity in multiple sclerosis but also impairs immune surveillance in the central nervous system, creating an environment permissive for JCV reactivation. The prescribing information includes a boxed warning stating that Tysabri increases the risk of PML (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Three known risk factors for PML in Tysabri-treated patients are: the presence of anti-JCV antibodies, longer treatment duration (especially beyond 2 years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Because of this risk, Tysabri is available only through a restricted distribution program called the TOUCH Prescribing Program, which requires patients to be enrolled, read a Medication Guide, understand the risks, and sign a Patient Enrollment Form (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Additionally, Tysabri increases the risk of herpes encephalitis and meningitis, with serious and sometimes fatal cases reported in the postmarketing setting (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

Mechanistic Pathways Linking Tysabri to PML

The mechanistic link between Tysabri and PML involves impaired immune surveillance. By blocking leukocyte trafficking into the brain, Tysabri reduces the ability of the immune system to control JCV, which is latent in many individuals. This allows JCV to reactivate and infect oligodendrocytes, leading to demyelination and neuronal damage. The risk is highest in patients with anti-JCV antibodies, indicating prior exposure to the virus, and increases with cumulative treatment duration. Prior immunosuppressant use further compromises immune function, compounding the risk.

Adequacy of Warnings Regarding Tysabri and PML

The prescribing information for Tysabri includes a boxed warning that clearly states the increased risk of PML and identifies the three major risk factors (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The TOUCH Prescribing Program is designed to ensure that patients are informed of these risks before starting treatment. However, questions about the adequacy of warnings may arise if patients were not adequately counseled about the specific risk factors, the need for regular monitoring, or the importance of reporting new symptoms promptly. For example, the warning emphasizes that healthcare professionals should monitor patients for any new sign or symptom suggestive of PML and withhold Tysabri immediately (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). If a patient developed PML without having been informed of these monitoring requirements, the adequacy of the warning could be contested.

Attorney-Related Considerations for Affected Patients

Patients who develop PML after Tysabri treatment may consider legal action based on claims of inadequate warning or failure to monitor. In New Jersey, the statute of limitations for personal injury claims, including those related to pharmaceutical products, is generally two years from the date the injury was discovered or should have been discovered. For PML, the timeline between exposure and documented harm is critical. PML can develop months to years after starting Tysabri, and symptoms may be initially misattributed to multiple sclerosis. The statute of limitations clock typically starts when the patient knows or reasonably should know that the injury was caused by Tysabri. Given the severity of PML, which usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962), affected patients or their families should seek legal counsel promptly to preserve their rights. Attorneys will need to establish the date of diagnosis, the duration of Tysabri therapy, and whether the patient was informed of the risk factors.

Timeline Between Exposure and Documented Harm

The risk of PML increases with longer treatment duration, especially beyond 2 years (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Cases have been reported after a few months to several years of therapy. For legal purposes, the relevant timeline includes the start of Tysabri treatment, the onset of PML symptoms, the date of definitive diagnosis, and the date the patient learned of the potential link to Tysabri. Medical records documenting anti-JCV antibody status, prior immunosuppressant use, and treatment duration are essential for establishing risk factors and causation.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the statute of limitations for Tysabri-related PML claims in New Jersey?

In New Jersey, the statute of limitations for personal injury claims, including those related to pharmaceutical products, is generally two years from the date the injury was discovered or should have been discovered. For PML, the clock typically starts when the patient knows or reasonably should know that the injury was caused by Tysabri.

What are the risk factors for developing PML while on Tysabri?

Three known risk factors for PML in Tysabri-treated patients are: the presence of anti-JCV antibodies, longer treatment duration (especially beyond 2 years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Tysabri exposure and a confirmed Progressive Multifocal Leukoencephalopathy diagnosis may request an independent eligibility review. [Begin Assessment]

References

Tysabri Prescribing Information - DailyMed

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.